New Therapies Set Stage for Dramatic Changes in Bladder Cancer
November 18th 2019The number of new therapies that have shown singleagent activity in metastatic disease, the earlier use of immune checkpoint blockade, and our continued attempts to refine our knowledge of the pathogenesis of urothelial carcinoma are expected to dramatically change treatment algorithms and outcomes over the next 5 to 10 years.
Read More